Data / Form D filings / Mivax Therapeutics, Inc.
Mivax Therapeutics, Inc.: Form D filings
Mivax Therapeutics, Inc., a biotechnology company in San Francisco, CA, filed 4 Form D notices with the SEC between 2025 and 2026. The latest, on January 23, 2026, reports $202,500 sold of a $500,000 offering to 21 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 701 CHINA BASIN ST APT 605, San Francisco, CA, 94158
- Phone
- (785) 770-6160
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2024
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2066303
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Amendment | $500,000 | $202,500 | $297,500 | 21 | Apr 17, 2025 | sec.gov |
| Jan 23, 2026 | Amendment | $500,000 | $107,500 | $392,500 | 21 | Apr 17, 2025 | sec.gov |
| May 2, 2025 | Amendment | $150,000 | $107,500 | $42,500 | 15 | Apr 17, 2025 | sec.gov |
| May 1, 2025 | New notice | Indefinite | $107,500 | 15 | Apr 17, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Viraj Balkrishna Deshpande | Executive Officer | President and Secretary |
| Pragyesh Dhungel | Executive Officer | Chief Executive Officer and Treasurer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jan 19, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Mivax Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.